[go: up one dir, main page]

AR050169A1 - Compuesto para el tratamiento de trastornos inflamatorios - Google Patents

Compuesto para el tratamiento de trastornos inflamatorios

Info

Publication number
AR050169A1
AR050169A1 ARP050102901A ARP050102901A AR050169A1 AR 050169 A1 AR050169 A1 AR 050169A1 AR P050102901 A ARP050102901 A AR P050102901A AR P050102901 A ARP050102901 A AR P050102901A AR 050169 A1 AR050169 A1 AR 050169A1
Authority
AR
Argentina
Prior art keywords
group
heterocyclyl
heteroaryl
aryl
alkyl
Prior art date
Application number
ARP050102901A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35134266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR050169A1 publication Critical patent/AR050169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente se refiere a su sal, solvato o isomero farmacéuticamente aceptable, los cuales pueden ser utiles para el tratamiento de enfermedades o afecciones mediadas por MMPs, ADAMs, TACE, TNF- o sus combinaciones. Reivindicacion 1: Un compuesto representado por la formula (1), o su sal, solvato o isomero farmacéuticamente aceptable, en donde: X se selecciona del grupo formado por -S-, -C(R4)2- o -N(R4)-; T se selecciona del grupo formado por H (estando U y V ausentes), alquilo, alquenilo, arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo, y arilalquilo, estando dicho arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo opcionalmente fusionado con una o más porciones seleccionadas del grupo formado por arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo, en donde cada uno de cualquiera de los grupos alquilo, alquenilo, arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo antes mencionados de T está no sustituido u opcional e independientemente sustituido con una a cuatro porciones R10 las cuales pueden ser iguales o diferentes, cada porcion R10 es independientemente seleccionada del grupo de porciones R10 que aparecen más adelante; U está ausente o presente, y si está presente U se selecciona del grupo formado por un enlace covalente, -N(R4)-, -N(R4)C(R4)2-, -N(R4)CO-, -O-, -N(R4)S(O)2-, -N(R4)C(O)N(R4)-, y -N(R4)C(S)N(R4)-; V está ausente o presente, y si está presente V se selecciona del grupo formado por alquilo, arilo, heteroarilo, heterociclilo y cicloalquilo, dicho arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo están opcionalmente fusionado con una o más porciones seleccionadas del grupo formado por arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo, en donde cada uno de cualquiera de los antes mencionados alquilo, arilo, heteroarilo, heterociclilo y cicloalquilo está no sustituido u opcional e independientemente sustituido con una a cuatro porciones R10 las cuales pueden ser iguales o diferentes, cada porcion R10 se seleccionada independientemente del grupo de porciones R10 que aparecen más adelante; Y está ausente o presente, y si está presente Y se selecciona del grupo formado por un enlace covalente, -(C(R4)2)n-, -N(R4)-, -C(O)N(R4)-, -N(R4)CO-, -N(R4)C(O)N(R4)-, -S(O)2N(R4)-, -N(R4)-S(O)2, -O-, -S-, -C(O)-, -S(O)-, y -S(O)2-; Z está ausente o presente, y si está presente Z se selecciona del grupo formado por un enlace covalente -(C(R4)2)n-, -N(R4)-, -C(O)N(R4)-, -N(R4)CO-, -N(R4)C(O)N(R4)-, -S(O)2N(R4)-, -N(R4)-S(O)2, -O-, -S-, -C(O)-, -S(O)-, y -S(O)2-; n es 1 a 3; R1 se selecciona del grupo formado por H, OR4, halogeno, alquilo, fluoralquilo, arilo, heteroarilo, heterociclilo, alquilarilo, alquilheteroarilo y arilalquilo, en donde cada uno de los grupos alquilo, fluoralquilo, arilo, heteroarilo, heterociclilo, alquilarilo, alquilheteroarilo y arilalquilo de R1 está no sustituido u opcional e independientemente sustituido con una a cuatro porciones R20 las cuales pueden ser iguales o diferentes, cada porcion R20 se selecciona independientemente del grupo de porciones R20 que aparecen más adelante, con la condicion de que cuando Y está presente e Y es N, S o O, entonces R1 no es halogeno; R2 se selecciona del grupo formado por H, -OR4, halogeno, alquilo, fluoralquilo, arilo, heteroarilo, heterociclilo, alquilarilo, alquilheteroarilo y arilalquilo, en donde cada uno de los grupos alquilo, fluoralquilo, arilo, heteroarilo, heterociclilo, alquilarilo, alquilheteroarilo y arilalquilo de R2 está no sustituido u opcional e independientemente sustituido con una a cuatro porciones R20 las cuales pueden ser iguales o diferentes, cada porcion R20 se selecciona independientemente del grupo de porciones R20 que aparecen más adelante, con la condicion de que cuando Z está presente y Z es N, S o O, entonces R2 no es halogeno; cada R4 es igual o diferente y se selecciona independientemente del grupo formado por H y alquilo; R10 se selecciona del grupo formado por -OR4, -N(R4)2, S(O)-, -S(O)2-, -N(R4)S(O)2-, -S(O)2N(R4)-, -O(fluoralquilo), halogeno, alquilo, fluoralquilo, arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo, en donde cada uno de los grupos alquilo, fluoralquilo, arilo, heteroarilo, heterociclilo, cicloalquilo, alquilarilo y arilalquilo de R10 está no sustituido u opcional e independientemente sustituido con una a cuatro porciones R30 las cuales pueden ser iguales o diferentes, cada porcion R30 se selecciona independientemente del grupo de porciones R30 que aparecen más adelante; R20 se selecciona del grupo formado por halogeno, alquilo, fluoralquilo; y R30 se selecciona del grupo formado por halogeno, alquilo, y fluoralquilo.
ARP050102901A 2004-07-16 2005-07-13 Compuesto para el tratamiento de trastornos inflamatorios AR050169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58850204P 2004-07-16 2004-07-16

Publications (1)

Publication Number Publication Date
AR050169A1 true AR050169A1 (es) 2006-10-04

Family

ID=35134266

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102901A AR050169A1 (es) 2004-07-16 2005-07-13 Compuesto para el tratamiento de trastornos inflamatorios

Country Status (21)

Country Link
US (2) US7482370B2 (es)
EP (1) EP1778676B1 (es)
JP (1) JP4943327B2 (es)
KR (1) KR20070032787A (es)
CN (1) CN101018782A (es)
AR (1) AR050169A1 (es)
AT (1) ATE478864T1 (es)
AU (1) AU2005275213A1 (es)
BR (1) BRPI0513433A (es)
CA (1) CA2573764A1 (es)
DE (1) DE602005023172D1 (es)
EC (1) ECSP077163A (es)
ES (1) ES2349041T3 (es)
IL (1) IL180736A0 (es)
MX (1) MX2007000668A (es)
NO (1) NO20070893L (es)
PE (1) PE20060561A1 (es)
RU (1) RU2007105685A (es)
TW (1) TWI297269B (es)
WO (1) WO2006019768A1 (es)
ZA (1) ZA200700384B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AU2005275213A1 (en) 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
MX2008002073A (es) * 2005-08-12 2008-04-16 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios.
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2007240568A1 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
US7998961B2 (en) 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
WO2009038784A1 (en) * 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
TW201024303A (en) * 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
TW201024304A (en) * 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
EP2355825A2 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US8541572B2 (en) 2008-11-10 2013-09-24 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory disorders
EP4289838A3 (en) 2010-02-11 2024-03-13 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HUE030114T2 (en) 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivatives and pharmaceutical compositions containing them
EP2651927A4 (en) * 2010-12-15 2014-06-04 Abbvie Inc ANTIVIRAL CONNECTIONS
AU2012242926B2 (en) * 2011-04-12 2016-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013085016A1 (ja) 2011-12-09 2013-06-13 科研製薬株式会社 ピリドン誘導体およびそれを含有する医薬
WO2013129622A1 (ja) 2012-03-02 2013-09-06 武田薬品工業株式会社 複素環化合物およびその用途
SI2925757T1 (en) 2012-11-19 2018-01-31 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
JP6211530B2 (ja) * 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
TWI636782B (zh) 2013-06-07 2018-10-01 科研製藥股份有限公司 （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
CA3015702A1 (en) 2015-09-02 2017-03-09 Trevena, Inc. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US10562887B2 (en) * 2016-05-27 2020-02-18 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of ROCK
CN108069942A (zh) * 2016-11-10 2018-05-25 四川大学 苯酞吡唑酮类偶联物、其制备方法和用途
EP3582783B1 (en) 2017-02-17 2023-06-07 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
KR20190129867A (ko) 2017-02-17 2019-11-20 트레베나, 인코포레이티드. 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
PT4058437T (pt) 2019-11-14 2025-02-10 Foresee Pharmaceuticals Usa Inc Inibidores de metaloproteinases de matriz (mmp) e métodos de uso dos mesmos

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110536A (en) * 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EE9900481A (et) * 1997-03-03 2000-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
JP2003507362A (ja) 1999-08-18 2003-02-25 ワーナー−ランバート・カンパニー マトリックスメタロプロテイナーゼ阻害剤として有用なヒドロキサム酸化合物
HK1049334B (en) 2000-03-17 2004-07-16 Bristol-Myers Squibb Pharma Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
SK10932003A3 (sk) 2001-03-15 2004-04-06 Astrazeneca Ab Metaloproteinázové inhibítory
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
US7294624B2 (en) 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
AU2003261319A1 (en) 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
EP1546109A4 (en) 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
AU2003297364B2 (en) 2002-12-19 2009-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of TACE
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AU2005275213A1 (en) 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7998961B2 (en) 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents

Also Published As

Publication number Publication date
JP4943327B2 (ja) 2012-05-30
ECSP077163A (es) 2007-02-28
WO2006019768A1 (en) 2006-02-23
RU2007105685A (ru) 2008-08-27
US7482370B2 (en) 2009-01-27
MX2007000668A (es) 2007-03-08
CN101018782A (zh) 2007-08-15
ES2349041T3 (es) 2010-12-22
IL180736A0 (en) 2007-06-03
PE20060561A1 (es) 2006-07-13
NO20070893L (no) 2007-04-13
ATE478864T1 (de) 2010-09-15
JP2008506692A (ja) 2008-03-06
EP1778676A1 (en) 2007-05-02
US7683085B2 (en) 2010-03-23
US20060205797A1 (en) 2006-09-14
TWI297269B (en) 2008-06-01
BRPI0513433A (pt) 2008-05-06
CA2573764A1 (en) 2006-02-23
TW200616620A (en) 2006-06-01
DE602005023172D1 (de) 2010-10-07
KR20070032787A (ko) 2007-03-22
ZA200700384B (en) 2008-09-25
US20090111803A1 (en) 2009-04-30
EP1778676B1 (en) 2010-08-25
AU2005275213A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
AR050169A1 (es) Compuesto para el tratamiento de trastornos inflamatorios
AR059036A1 (es) Compuestos para el tratamiento de trastornos inflamatorios
AR079783A1 (es) Derivados de tienopirrol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las proteinas quinasas
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR047976A1 (es) Compuestos inmunosupresores y composiciones
AR051094A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR039669A1 (es) Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad
AR060318A1 (es) Isoindolonas potenciadoras de receptores metabotropicos de glutamato, composiciones farmaceuticas que las comprenden y el uso de las mismas en la fabricacion de un medicamento para el tratamiento de trastornos neurologicos y psiquiatricos.
AR078756A1 (es) Moduladores alostericos positivos (map)
AR051026A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
ECSP066459A (es) Miméticos de glucocorticoides, métodos de preparación, composiciones farmacéuticas y usos de los mismos
ECSP045315A (es) MIMÉTICOS DE GlucocorticoidES, PROCEDIMIENTOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS Y USOS DE LOS MISMOS
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR075597A1 (es) Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas .
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
AR046600A1 (es) Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal